← Eichor
Study identifier: NCT05724446 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Condition: Cataracts Infantile  ·  Sponsor: Salvat

PhasePhase 3
Planned participants60
Who can joinAll sexes, 0 Months to 3 Years
Healthy volunteersNo

About this study

Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population. This study will assess the safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% to that of Prednisolone acetate, 1% when administering one drop four times a day (QID) for 14 days followed by a tapering period of 14 days after cataract surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Enrique Jimenez  ·  +34 933946400  ·  ejimenez@svt.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hospìtal Sant Joan de DeuBarcelona, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05724446